← Back to Search

mTOR inhibitor

Sirogen for Arteriovenous Fistula Outcomes (ACCESS2 Trial)

Phase 3
Recruiting
Research Sponsored by Vascular Therapies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Successful creation of a single stage radiocephalic end to side fistula
Age 65 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

ACCESS2 Trial Summary

This trial is testing whether a prophylactic treatment delivered during surgery can improve long-term outcomes for people needing hemodialysis.

Who is the study for?
This trial is for people aged 65 or older who have been on hemodialysis for less than a year and are getting a new arteriovenous fistula. It's not for those with previous AV access in the same limb, planned peritoneal dialysis soon, sirolimus or bovine collagen allergies, HIV positive individuals, prisoners, or substance abusers.Check my eligibility
What is being tested?
The study tests Sirogen—a Sirolimus eluting Collagen implant—given once during surgery to create an arteriovenous fistula used in hemodialysis. The goal is to see if this treatment can prevent complications related to vascular access.See study design
What are the potential side effects?
Potential side effects of Sirogen may include local reactions at the surgery site due to sirolimus or collagen components such as pain, swelling, infection risk increase and possibly allergic reactions in those sensitive to the ingredients.

ACCESS2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had a successful single stage radiocephalic fistula surgery.
Select...
I am 65 years old or older.
Select...
I have been on hemodialysis for 12 months or less.

ACCESS2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pathologic fistula

Side effects data

From 2008 Phase 4 trial • 293 Patients • NCT00118742
29%
Diarrhoea
18%
Abdominal Pain
16%
Nausea
16%
Headache
16%
Fatigue
16%
Hepatitis C
14%
Vomiting
14%
Pyrexia
14%
Leukopenia
12%
Oedema Peripheral
11%
Insomnia
10%
Anaemia
10%
Hyperkalaemia
10%
Tremor
10%
Back Pain
10%
Hypertension
9%
Cough
9%
Pruritis
9%
Arthralgia
8%
Neutropenia
8%
Abdominal Pain Upper
8%
Dizziness
8%
Pain in Extremity
8%
Hepatic Enzyme Increased
7%
Dyspnoea
7%
Constipation
7%
Sinusitis
7%
Weight Decreased
6%
Blood Creatinine Increased
6%
Liver Function Test Abnormal
6%
White Blood Cell Count Decreased
5%
Jaundice
5%
Renal Failure
5%
Muscle Spasms
5%
Decreased Appetite
5%
Weight Increased
5%
Upper Respiratory Tract Infection
5%
Nasopharyngitis
5%
Asthenia
5%
Incision Site Pain
5%
Depression
4%
Anorexia
4%
Night Sweats
4%
Oropharyngeal Pain
4%
Rhinorrhoea
3%
Myalgia
3%
Pleural Effusion
3%
Hyperlipidaemia
3%
Thrombocytopenia
3%
Rash
3%
Acne
3%
Incisional Hernia
2%
Sepsis
2%
Pneumonia
2%
Hypokalaemia
1%
Gastritis
1%
Urinary Retention
1%
Abdominal Hernia
1%
Multi-Organ Failure
1%
Benign Prostatic Hyperplasia
1%
Ventricular Tachycardia
1%
Non-Small Cell Lung Cancer Metastatic
1%
Hypoglycaemia
1%
Crohn's Disease
1%
Clostridium Difficile Colitis
1%
Inappropriate Antidiuretic Hormone Secretion
1%
Hepatic Neoplasm Malignant
1%
Blood Alkaline Phosphatase Increased
1%
Hepatic Failure
1%
Renal Failure Acute
1%
Chest Pain
1%
Cerebral Haemorrhage
1%
Gastrointestinal Haemorrhage
1%
Cardiac Failure Congestive
1%
Hepatic Artery Stenosis
1%
Portal Vein Thrombosis
1%
Epstein-Barr Virus Associated Lymphoproliferative Disorder
1%
Gastrointestinal Tract Adenoma
1%
Febrile Neutropenia
1%
Encephalopathy
1%
Atrial Flutter
1%
Blood Glucose Increased
1%
Transplant Rejection
1%
Confusional State
1%
Spinal Osteoarthritis
1%
Hypercholesterolaemia
1%
Convulsion
1%
Peritonitis
1%
Haemorrhage Intracranial
1%
Deep Vein Thrombosis
1%
Inguinal Hernia
1%
Viral Infection
1%
Acarodermatitis
1%
Atrial Fibrillation
1%
Malaise
1%
Hepatic Cancer Metastatic
1%
Adenocarcinoma
1%
B-Cell Lymphoma
1%
Desmoid Tumour
1%
Pulmonary Embolism
1%
Stomatitis
1%
Influenza
1%
Staphylococcal Infection
1%
Umbilical Hernia
1%
Hepatic Function Abnormal
1%
Hyponatraemia
1%
Bacteraemia
1%
Cellulitis
1%
Clostridial Infection
1%
Diverticulitis
1%
Escherichia Urinary Tract Infection
1%
Lactobacillus Infection
1%
Lobar Pneumonia
1%
Pseudomonal Sepsis
1%
Post Procedural Haemorrhage
1%
Procedural Pain
1%
Biliary Anastomosis Complication
1%
Complications of Transplanted Kidney
1%
Bile Duct Obstruction
1%
Bile Duct Stenosis
1%
Biliary Tract Disorder
1%
Autoimmune Hepatitis
1%
Cholestasis
1%
Lung Disorder
1%
Pulmonary Oedema
1%
Sinus Congestion
1%
Embolism Venous
1%
Orthostatic Hypotension
1%
Vasculitis
1%
Hyperglycaemia
1%
Graft Versus Host Disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
CellCept + CNI (Tacrolimus or Cyclosporine)
CellCept + Sirolimus

ACCESS2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment ArmExperimental Treatment1 Intervention
Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).
Group II: Control ArmActive Control1 Intervention
Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sirolimus
FDA approved

Find a Location

Who is running the clinical trial?

Vascular Therapies, Inc.Lead Sponsor
1 Previous Clinical Trials
269 Total Patients Enrolled
1 Trials studying Complication of Hemodialysis
269 Patients Enrolled for Complication of Hemodialysis
Sriram Iyer, MDStudy DirectorVascular Therapies, Inc.
3 Previous Clinical Trials
1,116 Total Patients Enrolled
1 Trials studying Complication of Hemodialysis
269 Patients Enrolled for Complication of Hemodialysis

Media Library

Sirolimus (mTOR inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05425056 — Phase 3
Complication of Hemodialysis Research Study Groups: Control Arm, Treatment Arm
Complication of Hemodialysis Clinical Trial 2023: Sirolimus Highlights & Side Effects. Trial Name: NCT05425056 — Phase 3
Sirolimus (mTOR inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05425056 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What sorts of risks are associated with Sirolimus?

"Sirolimus has been found to be safe in Phase 3 trials, and thus received a score of 3."

Answered by AI

How many potential test subjects are being considered for this experiment?

"Yes, the trial is still open and looking for patients. According to the clinicaltrials.gov website, the study was first posted on 8/26/2022 and updated on 9/28/2022. They are hoping to enroll 120 people at 15 different hospitals or clinics."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
2022. "A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05425056.
~46 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top